# US 2001/0034062 A1 · Antibody gene therapy with adeno-associated viral vectors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0034062 A1
- Document ID: US20010034062A1
- Status: Published application
- Kind: A1
- Application number: 09/781,052
- Filed: 2001-02-09
- Published: 2001-10-25
- Earliest claimed: 2000-02-09
- Inventors: Scott Koenig
- Web page: https://patentgrep.com/patent/US20010034062A1

## CPC

- C12N 15/86: Viral vectors
- A61P 11/06: Antiasthmatics
- A61P 27/00: Drugs for disorders of the senses
- A61P 31/20: for DNA viruses
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 16/11: Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
- C07K 16/2848: {against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2039/505: {comprising antibodies}
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2799/022: where the vector is derived from an adenovirus
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods are disclosed for treating and/or preventing diseases, both infectious and chronic. Infectious diseases combated by the methods disclosed herein include microbial caused diseases, especially diseases of the respiratory system, including those diseases caused, induced or otherwise mediated by viruses, bacteria, fungi and other parasites. The present invention also discloses vectors useful in the treatment and/or prevention of such conditions. The vectors disclosed herein are recombinant viral vectors comprising genetically engineered adeno-associated viruses comprising genetic sequences coding for antibody molecules and portions thereof, which antibodies are useful in combating or preventing infectious and chronic diseases, such as respiratory diseases, including asthma, as well as ophthalmic diseases, including age related and diabetes-related macular degeneration and other retinopathies.

## Claims

### Claim 1

A recombinant adeno-associated virus (rAAV) vector whose genome comprises one or more polynucleotide sequences encoding at least one polypeptide of an antibody wherein said polynucleotide is operably linked to control elements that direct intracellular transcription and translation of said polynucleotide when said rAAV is inserted into a mammalian cell.

### Claim 2 (depends on 1)

The vector of claim 1 wherein said polypeptide is the light chain of said antibody.

### Claim 3 (depends on 1)

The vector of claim 1 wherein said polypeptide is the heavy chain of said antibody.

### Claim 4 (depends on 1)

The vector of claim 1 wherein said polynucleotide encodes both a heavy and a light chain of said antibody.

### Claim 5 (depends on 1)

The vector of claim 1 wherein said antibody is specific for at least one epitope found on a microbial organism.

### Claim 6 (depends on 5)

The vector of claim 5 wherein said microbe is selected from the group consisting of viruses, bacteria, fungi and parasites.

### Claim 7 (depends on 6)

The vector of claim 6 wherein said microbe is a virus.

### Claim 8 (depends on 7)

The vector of claim 7 wherein said virus is selected from the group consisting of respiratory syncytial virus (RSV) and parainfluenza virus (PIV).

### Claim 9 (depends on 5)

The vector of claim 5 wherein said microbial organism causes or induces a disease or inflammation of the respiratory system.

### Claim 10 (depends on 9)

The vector of claim 9 wherein the disease is selected from the group consisting of bronchitis, bronchiolitis and pneumonia.

### Claim 11 (depends on 5)

The vector of claim 5 wherein said antibody is selected from the group consisting of CH1129, H1129, M1129, M1308F, H1308F, and MEDI493.

### Claim 12 (depends on 1)

The vector of claim 1 wherein said antibody is an antibody involved in mediating a non-infectious disease of the respiratory system.

### Claim 13 (depends on 12)

The vector of claim 12 wherein said disease is selected from the group consisting of asthma, allergies, and cystic fibrosis.

### Claim 14 (depends on 1)

The vector of claim 1 wherein said antibody is selected from the group consisting of anti-interleukin-9 (anti-IL-9), anti-interleukin-9-receptor (anti-IL-9-r), anti-Ras protein and vitaxin II.

### Claim 15 (depends on 1)

The vector of claim 1 wherein said antibody is an antibody having a therapeutic effect on diseases or inflammations of the ophthalmic system.

### Claim 16 (depends on 1)

A composition comprising a therapeutic amount of the recombinant vectors of claim 1 suspended in a pharmacologically acceptable carrier.

### Claim 17 (depends on 16)

A method of treating a disease in a patient afflicted therewith comprising administering to said patient a therapeutic amount of the composition of claim 16.

### Claim 18 (depends on 17)

The method of claim 17 wherein said administration comprises injecting a sample of said recombinant AAV into the tissues of said patient.

### Claim 19 (depends on 18)

The method of claim 18 wherein said tissues are selected from the group consisting of respiratory tissue, muscle tissue, and ophthalmic tissue.

### Claim 20 (depends on 17)

The method of claim 17 wherein said disease is selected from the group consisting of viral infection, asthma, allergy, and macular degeneration.

### Claim 21 (depends on 1)

A recombinant cell whose genome comprises one or more rAAV vectors of claim 1.

### Claim 22 (depends on 21)

The recombinant cell of claim 21 wherein said cell produces the polypeptide encoded by the polynucleotide contained in the genome of said rAAV particles.

### Claim 23 (depends on 22)

The recombinant cell of claim 22 wherein said cell is selected from the group consisting of muscle cells, respiratory cells, ophthalmic cells.

### Claim 24 (depends on 22)

A method of treating a respiratory disease in a patient comprising administering to said patient a therapeutic amount of the recombinant cells of claim 22.
